Supportive Care in Radiotherapy Based on a Mobile App: Prospective Multicenter Survey.
Supportive Care in Radiotherapy Based on a Mobile App: Prospective Multicenter Survey.
复制标题
DOI：
10.2196/10916
复制
发表时间：
2018-08-30
影响因子：
5
通讯作者：
Nicolay NH
中科院分区：
文献类型：
--
作者：
El Shafie RA;Weber D;Bougatf N;Sprave T;Oetzel D;Huber PE;Debus J;Nicolay NH
消费电子产品和具有网络功能的移动设备在患者护理中发挥着越来越大的作用，它们在肿瘤学领域的使用为支持性癌症护理和系统的患者随访领域开辟了前景广阔的可能性。我们研究的目的是评估基于移动应用程序的概念对接受放射治疗的癌症患者的支持性护理的接受度和可能的好处。总共有975名因乳腺癌或前列腺癌而接受放射治疗的患者接受了筛查；其中200人拥有智能手机，并同意参与调查。要求患者在放疗开始前(T0)和放疗结束后(T1)两个时间点完成问卷调查。调查问卷包括以下问题：智能手机的使用习惯、参与者的技术知识和能力、在放射治疗背景下使用移动应用的准备情况、移动应用的可能功能，以及对肿瘤治疗不同方面的总体态度。对于定量分析，计算所有感兴趣区域的总分，结果与患者特征相关。此外，还对时间点T0和T1之间的答案进行了定量比较。患者的平均年龄为57岁(范围27-78岁)。在200名参与者中，131名(66.2%)报告说他们能够在几乎没有帮助的情况下使用他们的智能手机，75.8%(150/200)的人以前没有在医疗环境中使用过他们的智能手机。然而，73.3%(146/200)和83.4%(166/200)的患者在放疗期间和临床随访期间分别对使用移动应用程序进行支持性护理表现出浓厚的兴趣。患者最常要求的功能是在诊所预约(176/200，88.0%)和收集患者报告的关于他们的疾病、治疗和总体幸福感的结果数据(130/200，65.0%)。年龄被认为是影响患者态度的最大因素，55岁的患者明显更倾向于和精通智能手机的使用(P<；.001)。在卡诺夫斯基绩效指数为80%的患者中，移动应用程序的接受度显著更高(P=.01)。在治疗相关副作用的背景下，临床表现较差的患者认为支持最重要(P=.006)。在放射治疗监测方面，移动应用程序的总体接受度很高，项目总分的中位数为71.4/100，并且不受肿瘤分期、年龄、性别、治疗环境或既往放射治疗的显著影响。对于接受放射治疗的癌症患者的监测和随访，移动应用程序的接受度很高；这一高接受度将作为未来临床试验的基础，调查基于移动应用程序的治疗支持的临床好处。将移动应用程序引入临床常规应被视为改善和加强对癌症患者的支持治疗的机会。
Consumer electronics and Web-enabled mobile devices are playing an increasing role in patient care, and their use in the oncologic sector opens up promising possibilities in the fields of supportive cancer care and systematic patient follow-up. The objective of our study was to assess the acceptance and possible benefits of a mobile app–based concept for supportive care of cancer patients undergoing radiotherapy. In total, 975 patients presenting for radiotherapy due to breast or prostate cancer were screened; of them, 200 owned a smartphone and consented to participate in the survey. Patients were requested to complete a questionnaire at 2 time points: prior to the initiation (T0) and after the completion (T1) of radiotherapy. The questionnaire included questions about the habits of smartphone usage, technical knowledge and abilities of the participants, readiness to use a mobile app within the context of radiotherapy, possible features of the mobile app, and general attitude toward the different aspects of oncologic treatments. For quantitative analysis, sum scores were calculated for all areas of interest, and results were correlated with patient characteristics. Additionally, answers were quantitatively compared between time points T0 and T1. Median patient age was 57 (range 27-78) years. Of the 200 participants, 131 (66.2%) reported having the ability to use their smartphones with minimal to no help and 75.8% (150/200) had not used their smartphones in a medical context before. However, 73.3% (146/200) and 83.4% (166/200) of patients showed a strong interest in using a mobile app for supportive care during radiotherapy and as part of the clinical follow-up, respectively. Patients most commonly requested functionalities regarding appointment scheduling in the clinic (176/200, 88.0%) and the collection of patient-reported outcome data regarding their illness, therapy, and general well-being (130/200, 65.0%). Age was identified as the most influential factor regarding patient attitude, with patients aged <55 years being significantly more inclined toward and versed in smartphone use (P<.001). The acceptance of mobile apps was significantly higher in patients exhibiting a Karnofsky performance index <80% (P=.01). Support in the context of therapy-related side effects was judged most important by patients with poor clinical performance (P=.006). The overall acceptance of mobile apps in the context of radiotherapy surveillance was high at a median item sum score of 71.4/100 and was not significantly influenced by tumor stage, age, gender, treatment setting, or previous radiotherapies. The acceptance of mobile apps for the surveillance and follow-up of cancer patients undergoing radiotherapy is high; this high acceptance level will serve as a basis for future clinical trials investigating the clinical benefits of mobile app–based treatment support. Introduction of mobile apps into the clinical routine should be considered as an opportunity to improve and intensify supportive treatment for cancer patients.
登录
查看更多内容
影响因子：
5
作者：
Argent R;Daly A;Caulfield B
通讯作者：
Caulfield B
影响因子：
7.4
作者：
Bender JL;Yue RY;To MJ;Deacken L;Jadad AR
通讯作者：
Jadad AR
影响因子：
4.4
作者：
Brouard, Benoit;Bardo, Pascale;Vignot, Stephane
通讯作者：
Vignot, Stephane
影响因子：
3
作者：
MCHORNEY, CA;WARE, JE;RACZEK, AE
通讯作者：
RACZEK, AE
影响因子：
7.4
作者：
Carroll JK;Moorhead A;Bond R;LeBlanc WG;Petrella RJ;Fiscella K
通讯作者：
Fiscella K